You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股個別發展 藥明合聯再創新高 來凱醫藥跌20%
恆指午後跌幅收窄至48點或0.3%,報17,511,總成交額554億元。 醫藥股個別發展,百心安-B(02185.HK)高見4.56元,現報4.44元,回升7%。藥明巨諾-B(02126.HK)先跌後回升,午後重上10天線(2.59元),最高見2.72元,現報2.7元,升6.3%;藍籌藥明生物(02269.HK)連跌三日後,今早低見44.25元,一度失守百天線(44.3元),其後回升,現報46.5元,升3.5%;掛牌第七天的藥明合聯(02268.HK)再創新高,最高見29.6元,現報29.25元,升0.9%。 信達生物(01801.HK)報44.85元,升2.5%;百濟神州(06160.HK)報110.1元,升1.2%。再鼎醫藥(09688.HK)及康方生物(09926.HK)分別升1.4%及2.2%,報22.15元及47.9元。先聲藥業(02096.HK)升1%報7.36元。 開拓藥業-B(09939.HK)脫髮藥與安慰劑相比,未達顯著性差異,該股破底,低見2.01元、創上市新低,現報2.34元,急挫近31%,成交增至7,557萬股。 半新股來凱醫藥-B(02105.HK)失守10天及20天線,最低見18.1元,現報18.2元,跌20%。 君實(01877.HK)、騰盛博藥-B(02137.HK)、上海醫藥(02607.HK)、復星醫藥(02196.HK)及諾誠健華-B(09969.HK)跌逾2%-3.5%,當中復星醫藥及諾誠健華沽壓較大,分別報17.82元及6.63元,跌3.5%及4.2%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account